ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,335.81
-0.28%
Dow Jones
44,998.71
0.66%
Gold vs US Dollar
2,649.475
0.25%
Brent Oil
72.475
-1.54%
Bitcoin
98,528.62
2.67%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IO Biotech Inc (IOBT) Share Price

IOBT IO Biotech Inc

0.8252
-0.035 (-4.07%)
Last Updated: 20:18:05
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 IO Biotech Inc NASDAQ:IOBT NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.035 -4.07 0.8252 0.8205 0.8299 0.90 0.8003 0.841 330,267 20:18:05   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -86.08M -1.3066 -0.64 56.67M
 Type  Size  Price  Time  Units 
  100 0.8252 20:18:05 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore IOBT News
12/11/202421:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202412:11EDGAR2Form 8-K - Current report
12/11/202412:05GLOBEIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
11/11/202421:05GLOBEIO Biotech Announces Participation in Upcoming Investor Conferences
07/11/202415:00GLOBEIO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
04/10/202413:00GLOBEIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
14/09/202406:30GLOBEIO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Period
Draw mode
Data Downloads for IOBT

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest IO Biotech Inc Articles